CTIS2023-509380-24-00招募中1 期
Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer(AuspiCiOus-dMMR): a proof-of-principle study
Amsterdam UMC0 个研究点目标入组 25 人开始时间: 2024年3月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •? Patients must provide written informed consent according to ICH/GCP, and national/local regulations prior to any screening procedures. ? dMMR identified by IHC of mismatch repair proteins MLH1, PMS2, MSH2 en MSH6 ? Primary tumor or metastasis accessible for repeat fresh histological biopsies ? Male or female adult patients (> 18 years). ? Patients with histologically confirmed diagnosis of metastatic or irresectable HER2 negative adenocarcinoma of the stomach or oesophagus, patients with HER2 positive disease are eligible when treatment with trastuzumab is contraindicated. ? Patients with metastatic or irresectable adenocarcinoma of the stomach or oesophageal junction (Siewert II or III) not pre-treated with chemotherapy or radiotherapy for irresectable or metastatic disease. Palliative radiotherapy on the primary tumor or a metastatic lesion is allowed if other untreated lesions for RECIST evaluation are present. Chemoradiation with carboplatin area under the curve (AUC) 2 and paclitaxel 50 mg/m2 for irresectable disease is allowed if subsequent disease progression is proven on radiological imaging. ? Measurable/evaluable disease as assessed by RECIST 1.1 ? ECOG (WHO) performance status 0-2 ? Adequate hepatic, renal and hematological function
排除标准
- •? Severe renal impairment (CLcr = 30 ml/min) ? Any clinically significant disorder impacting the risk-benefit balance negatively per physician’s judgment. ? Presence of additional malignancy that is progressing or has required active treatment in the last 5 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that have undergone potentially curative therapy are not excluded. ? Active autoimmune disease that has required systemic treatment in past 2 years, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. ? Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention. ? Any clinically significant gastrointestinal disorder, including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 2. ? Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) in last 6 months. ? NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure. Or known abnormal ECG with clinically significant abnormal findings. ? Active infection or an unexplained fever >38.5°C (excluding tumor fever), which in the physician’s opinion might compromise the patient’s health. ? Current use or any use in last two weeks of strong CYP3A-enzyme, CYP2C8, and/or strong UGT1A inhibitors/inducers. ? Known hypersensitivity or contraindications to any of the components of capecitabine or oxaliplatin. ? History of severe and unexpected reactions to fluoropyrimidine therapy. ? Known complete dihydropyrimidine dehydrogenase (DPD) deficiency. ? Breast feeding, known pregnancy, positive serum pregnancy test or unwillingness to use a reliable method of birth control, during therapy and for 3 months following the last dose of cytotoxic agents. ? Treatment within 4 weeks with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine. ? Pre-existing motor or sensory neurotoxicity greater than WHO grade 1. ? History of organ transplant, including allogeneic stem cell transplantation. ? Receiving probiotics as of the first dose of study treatment.
研究者
相似试验
招募中
2 期
Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle studyNL-OMON52108Academisch Medisch Centrum25
进行中（未招募）
1 期
Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cellsGastroesophageal cancerEUCTR2021-001181-38-NLAcademic Medical Center25
招募中
2 期
eoadjuvant capecitabine, oxaliplatin, docetaxel and atezolizumab in non-metastatic, resectable gastric and GE-junction cancer. ;The PANDA trialgastric cancerstomach cancer10017990NL-OMON50269ederlands Kanker Instituut20
招募中
2 期
Pre-operative capecitabine, oxaliplatin, docetaxel and atezolizumab in gastric cancer (PANDA)2024-519075-26-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting21
招募中
2 期
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)Gastric AdenocarcinomaEsophageal AdenocarcinomaNCT05177133Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)25